Table of Contents
Review
| Radiotherapy in combination with systemic therapies for brain metastases: current status and progress | |
| Lei Liu, et al. | 1-13 |
| Current management of chemotherapy-induced neutropenia in adults: key points and new challenges | |
| Yi Ba, et al. | 1-14 |
| Evolving insights: How DNA repair pathways impact cancer evolution | |
| Jiadong Zhou, et al. | 1-22 |
| Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects | |
| Armel H. Nwabo Kamdje, et al. | 1-14 |
| Adaptive response of resistant cancer cells to chemotherapy | |
| Yi-Jye Chern, et al. | 1-22 |
Original Article
| Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines | |
| Natalia Vargas-Rondón, et al. | 1-22 |
| Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer | |
| Jing Zhao, et al. | 1-13 |
| The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization | |
| Huadan Xu, et al. | 1-13 |
| The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer | |
| Yue Fan, et al. | 1-19 |
| The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency | |
| Yayun Gu, et al. | 1-14 |
| The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics | |
| Xiaotian Shen, et al. | 1-16 |
| Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma | |
| Ting Han, et al. | 1-17 |
OUR FRIENDS
